Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc. PR Newswire NEW YORK , Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition com...
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer - Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases PR N...
Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger PR Newswire PHILADELPHIA and NEW YORK , Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close ...
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BA...
PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BA...
PHILADELPHIA, June 29, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BA...
PHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS ...
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. - Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) - - Upon closing, the combined company is expected to receive up to $116 million in ...
News, Short Squeeze, Breakout and More Instantly...
Chardan Healthcare Acquisition 2 Corp. Company Name:
CHAQ Stock Symbol:
NYSE Market:
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc. PR Newswire NEW YORK , Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition com...
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer - Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases PR N...
Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger PR Newswire PHILADELPHIA and NEW YORK , Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close ...